Germany to Charge Most Citizens for COVID Rapid Tests (representational image - VOA)
Germany to Charge Most Citizens for COVID Rapid Tests (representational image - VOA) 
Medicine

Germany to Charge Most Citizens for COVID Rapid Tests

MedBound Times

Germany will start charging for rapid COVID-19 tests that were previously free, though vulnerable groups will be exempt from the fee.

Germany will start charging for rapid COVID-19 tests that were previously free (representational image - Wikimedia)

Health Minister Karl Lauterbach said that starting July 1 the rapid tests widely available at centers across Germany will cost citizens 3 euros ($3.16) each, with the rest subsidized by the government.

The tests will remain free for people who can prove they belong to vulnerable groups, for visitors to care homes and hospitals, and for small children.

Join MedBound - an ecosystem for students and professionals of medical and health sciences.

The planned end to free tests at the end of June has raised concerns that Germany might experience an undetected rise in coronavirus cases over the coming months as people unwittingly spread the virus.

Lauterbach said the government has calculated that subsidies for the tests will cost some 2.6 billion euros in the second half of the year — about a third of what it paid in the same period of 2021.

Lauterbach said the government has calculated that subsidies for the tests will cost some 2.6 billion euros in the second half of the year (representational image - Wikimedia)

Germany on Friday recorded over 108,000 newly confirmed COVID-19 cases in 24 hours, and 90 additional deaths.(AS/VOA)

Also read Scientists treat prolonged COVID with human breast milk

Long-term COVID: Yoga & Naturopathy to the rescue

New Study Shows Loneliness Linked to Higher Mortality in Cancer Survivors

Are Magic Mushrooms a Safe Alternative to Treat Medication-resistant Depression?

Virtual Reality Program Educates Dialysis Patients on Cooking, Shopping

Social Media Can Influence People’s Views on Mental Illness

In Psychedelic Therapy, Clinician-Patient Bond May Matter Most